Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vicarious Surgical Inc. filings document the company's robotic surgery business, capital structure, governance actions, and public-market status. Recent 8-K reports cover operating results, financial condition, executive employment agreement amendments, and NYSE delisting proceedings for the company's Class A common stock, which is quoted on the OTC market under RBOT.
Proxy and shareholder-vote filings describe amendments to the certificate of incorporation related to a reverse stock split authorization and the voting mechanics of the company's Class A and Class B common stock. Form 25 and related reports document removal of the Class A common stock from NYSE listing and registration under Section 12(b).
Sammy Khalifa reported intent to sell Class A common stock with a listed sale date of 03/02/2026 described as a Restricted Stock Lapse. The excerpt also lists prior securities sold in the past three months: 239 shares on 12/03/2025 and 754 shares on 02/20/2026.
This Form 144 notice names the security as Class A Common Stock and shows broker details for UBS Financial Services. The filing is a routine insider disposition notice stating planned and recent transactions; timing and proceeds detail beyond the dates and share counts above are not shown in the excerpt.
Vicarious Surgical Inc filed a Form 144 reporting a proposed sale of 1,348 shares of Class A common stock.
The filing lists the sale method as Restricted Stock Lapse dated 03/02/2026 and names UBS Financial Services Inc. It also discloses prior sales of 463 shares on 12/03/2025 and 942 shares on 02/20/2026.
Vicarious Surgical Inc. President and director Adam David Sachs reported an open-market sale of 942 shares of Class A Common Stock on February 20, 2026, at a weighted average price of $2.0878 per share. After this transaction, he held 46,943 shares directly.
The sale was executed under a mandated “sell to cover” arrangement to satisfy tax withholding obligations from vesting restricted stock units granted on May 19, 2022, and did not represent a discretionary trade by Sachs.
Vicarious Surgical Inc. director and Chief Technology Officer Sammy Khalifa reported an open-market sale of 754 shares of Class A common stock. The shares were sold at a weighted average price of $2.0841 per share, leaving 32,869 shares of Class A common stock held directly after the transaction.
According to the disclosure, this sale was executed solely to cover tax withholding obligations related to the vesting of restricted stock units granted on May 19, 2022, under the company’s equity incentive plan. The filing notes this was a mandated “sell to cover” transaction and not a discretionary trade by the reporting person.
Vicarious Surgical Inc. filing a Rule 144 notice that lists the proposed sale of 1,902 shares of Class A common stock following a 02/19/2026 restricted stock lapse. The broker shown is UBS Financial Services with a filing date of 02/20/2026.
The filing also reports prior sales of 239 shares on 12/03/2025 by Sammy Khalifa. The notice records standard transaction details for an insider sale under Rule 144.
Vicarious Surgical Inc. filed a Rule 144 notice indicating proposed sales of Class A common stock. The filing lists 2,377 shares tied to a restricted stock lapse on 02/19/2026. It also records a prior sale of 463 shares on 12/03/2025 by Adam Sachs.
Vicarious Surgical Inc. filed an 8-K describing updated severance and change in control protections for its Chief Executive Officer and Chief Financial Officer. CEO Stephen From received an amendment to his employment agreement that provides severance if he is terminated without cause or resigns for good reason, including enhanced cash payments, continued COBRA health premiums and full vesting of time-based equity if the termination occurs in connection with a change in control.
CFO Sarah Romano entered into a new Executive Severance and Change in Control Agreement with similar protections, scaled to her role. Her agreement also offers higher severance multiples, extended COBRA coverage and full vesting of time-based equity awards if a qualifying termination occurs within a defined window around a change in control. Both arrangements require signing a separation agreement with a release and restrictive covenants.
Vicarious Surgical Inc. reported the results of a special stockholder meeting held on January 9, 2026. Stockholders voted on a single proposal related to warrants previously issued by the company.
Holders of Class A and Class B common stock, voting together as a single class, approved the exercise of warrants issued on October 7, 2025 to purchase up to an aggregate of 2,300,000 shares of Class A common stock. The proposal passed with 14,991,093 votes in favor, 23,052 votes against, and 2,894 abstentions.
There were 2,591,229 shares of Class A and Class B common stock present or represented by proxy at the meeting, representing approximately 78.18% of the outstanding total voting power entitled to vote, which was sufficient to constitute a quorum.
Vicarious Surgical Inc. is offering up to $3,000,000 of Class A common stock through an at-the-market program under an existing $100,000,000 shelf registration. The shares will be sold from time to time on the New York Stock Exchange or other U.S. trading markets through H.C. Wainwright & Co. as sales agent or principal, earning a 3.0% commission on gross proceeds. Based on a recent NYSE price of $2.17, this would represent up to 1,382,488 shares, with total Class A shares outstanding potentially rising to 7,845,739, though actual issuance will depend on future trading prices and sale decisions.
The company plans to use any net proceeds for general corporate purposes, including working capital, capital spending, and research and development or clinical trial costs, and may also fund possible acquisitions or strategic investments. Vicarious Surgical is developing a single-port robotic surgical system that has not yet been authorized by the FDA and remains in a pre-commercial, development-focused stage. The company has an NYSE compliance plan in place after previously falling below market capitalization and equity listing thresholds, and warns that investors face significant risks, including dilution and share price volatility.